comparison of glp-1 agonists Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults GLP-1 medications compared: Benefits and

Similarly, Wegovy and Zepbound also generate interest specifically for weight management treatments

[DOI] [PubMed] [Google Scholar] 92.Coskun T, et al

These positive results indicate that the change in myocardial cells may not be the primary driver of HFpEF

Patients with indicators of high-risk or established ASCVD, chronic kidney disease, or heart failure According to the ADA, when considering an agent for add-on to metformin background therapy, the first recommended consideration is whether or not the patient has indicators of high-risk or established ASCVD, chronic kidney disease (CKD), or heart failure ( Figure 2 )

[13] Singh, S., & Bajaj, V

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes